Form D · Biotechnology

Ensho Therapeutics, Inc.

Woodcliff Lake, NJ · CIK 0002032849

Offering snapshot reported Oct 15, 2026 · SEC filing

Reported sold
$7.28M
Offering amount: $15.6M
Investors reported
7
Form D · investor count
Minimum accepted
$1
Reported outside-investor minimum
First sale
Oct 2, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 15, 2026Initial$7,281,948No comparison7SEC filing
Feb 9, 2026Initial$0No comparison9SEC filing
Sep 12, 2025Initial$22,500,000No comparison2SEC filing
Nov 12, 2024Initial$5,000,000No comparison1SEC filing
Aug 6, 2024Initial$400,000No comparison2SEC filing

Offering details

Securities
Equity, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-601479

Source: Form D, filed Oct 15, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Neena Bitritto Garg Director
Danielle Fry Executive
Gerhard Hagn Director
Bittoo Kanwar Executive
Tariq Kassum Director
Matthew Mc Kevitt Executive
Eric Pham Director
Arash Rassoulpour Director
Carlos Solorzano Director
Emily Weng Executive
James Whitney Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
50 Tice Boulevard Suite 340 #1005
Woodcliff Lake, NJ, 07677
Phone: 973-475-8970